269 related articles for article (PubMed ID: 31331301)
1. The design, analysis and application of mouse clinical trials in oncology drug development.
Guo S; Jiang X; Mao B; Li QX
BMC Cancer; 2019 Jul; 19(1):718. PubMed ID: 31331301
[TBL] [Abstract][Full Text] [Related]
2. On the Choice of Longitudinal Models for the Analysis of Antitumor Efficacy in Mouse Clinical Trials of Patient-derived Xenograft Models.
Savel H; Barbier S; Proust-Lima C; Rondeau V; Thiébaut R; Meyer-Losic F; Richert L
Cancer Res Commun; 2023 Jan; 3(1):140-147. PubMed ID: 36968232
[TBL] [Abstract][Full Text] [Related]
3. Molecular and clinical implementations of ovarian cancer mouse avatar models.
Zayed AA; Mandrekar SJ; Haluska P
Chin Clin Oncol; 2015 Sep; 4(3):30. PubMed ID: 26408297
[TBL] [Abstract][Full Text] [Related]
4. Report of the use of patient-derived xenograft models in the development of anticancer drugs in Japan.
Tsumura R; Koga Y; Hamada A; Kuwata T; Sasaki H; Doi T; Aikawa K; Ohashi A; Katano I; Ikarashi Y; Ito M; Ochiai A
Cancer Sci; 2020 Sep; 111(9):3386-3394. PubMed ID: 32639672
[TBL] [Abstract][Full Text] [Related]
5. Dose escalation methods in phase I cancer clinical trials.
Le Tourneau C; Lee JJ; Siu LL
J Natl Cancer Inst; 2009 May; 101(10):708-20. PubMed ID: 19436029
[TBL] [Abstract][Full Text] [Related]
6. Advancing cancer drug development through precision medicine and innovative designs.
Zhang W; Wang J; Menon S
J Biopharm Stat; 2018; 28(2):229-244. PubMed ID: 29173004
[TBL] [Abstract][Full Text] [Related]
7. Movember GAP1 PDX project: An international collection of serially transplantable prostate cancer patient-derived xenograft (PDX) models.
Navone NM; van Weerden WM; Vessella RL; Williams ED; Wang Y; Isaacs JT; Nguyen HM; Culig Z; van der Pluijm G; Rentsch CA; Marques RB; de Ridder CMA; Bubendorf L; Thalmann GN; Brennen WN; Santer FR; Moser PL; Shepherd P; Efstathiou E; Xue H; Lin D; Buijs J; Bosse T; Collins A; Maitland N; Buzza M; Kouspou M; Achtman A; Taylor RA; Risbridger G; Corey E
Prostate; 2018 Dec; 78(16):1262-1282. PubMed ID: 30073676
[TBL] [Abstract][Full Text] [Related]
8. A mouse model for evaluation of efficacy and concomitant toxicity of anti-human CXCR4 therapeutics.
Costa MJ; Kudaravalli J; Liu WH; Stock J; Kong S; Liu SH
PLoS One; 2018; 13(3):e0194688. PubMed ID: 29554149
[TBL] [Abstract][Full Text] [Related]
9. From waterfall plots to spaghetti plots in early oncology clinical development.
Mercier F; Consalvo N; Frey N; Phipps A; Ribba B
Pharm Stat; 2019 Oct; 18(5):526-532. PubMed ID: 30942559
[TBL] [Abstract][Full Text] [Related]
10. Drug delivery to solid tumors: the predictive value of the multicellular tumor spheroid model for nanomedicine screening.
Millard M; Yakavets I; Zorin V; Kulmukhamedova A; Marchal S; Bezdetnaya L
Int J Nanomedicine; 2017; 12():7993-8007. PubMed ID: 29184400
[TBL] [Abstract][Full Text] [Related]
11. Development and use of biomarkers in oncology drug development.
Floyd E; McShane TM
Toxicol Pathol; 2004; 32 Suppl 1():106-15. PubMed ID: 15209410
[TBL] [Abstract][Full Text] [Related]
12. Development and Applications of Patient-Derived Xenograft Models in Humanized Mice for Oncology and Immune-Oncology Drug Discovery.
Verma B; Ritchie M; Mancini M
Curr Protoc Pharmacol; 2017 Sep; 78():14.41.1-14.41.12. PubMed ID: 28892144
[TBL] [Abstract][Full Text] [Related]
13. Biomarker- versus drug-driven tumor growth inhibition models: an equivalence analysis.
Sardu ML; Poggesi I; De Nicolao G
J Pharmacokinet Pharmacodyn; 2015 Dec; 42(6):611-26. PubMed ID: 26209955
[TBL] [Abstract][Full Text] [Related]
14. Whole transcriptome profiling of patient-derived xenograft models as a tool to identify both tumor and stromal specific biomarkers.
Bradford JR; Wappett M; Beran G; Logie A; Delpuech O; Brown H; Boros J; Camp NJ; McEwen R; Mazzola AM; D'Cruz C; Barry ST
Oncotarget; 2016 Apr; 7(15):20773-87. PubMed ID: 26980748
[TBL] [Abstract][Full Text] [Related]
15. Biomarker driven population enrichment for adaptive oncology trials with time to event endpoints.
Mehta C; Schäfer H; Daniel H; Irle S
Stat Med; 2014 Nov; 33(26):4515-31. PubMed ID: 25130879
[TBL] [Abstract][Full Text] [Related]
16. Statistical analysis of comparative tumor growth repeated measures experiments in the ovarian cancer patient derived xenograft (PDX) setting.
Oberg AL; Heinzen EP; Hou X; Al Hilli MM; Hurley RM; Wahner Hendrickson AE; Goergen KM; Larson MC; Becker MA; Eckel-Passow JE; Maurer MJ; Kaufmann SH; Haluska P; Weroha SJ
Sci Rep; 2021 Apr; 11(1):8076. PubMed ID: 33850213
[TBL] [Abstract][Full Text] [Related]
17. Early-drug development in the era of immuno-oncology: are we ready to face the challenges?
Ochoa de Olza M; Oliva M; Hierro C; Matos I; Martin-Liberal J; Garralda E
Ann Oncol; 2018 Aug; 29(8):1727-1740. PubMed ID: 29945232
[TBL] [Abstract][Full Text] [Related]
18. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
[TBL] [Abstract][Full Text] [Related]
19. US cancer institute to overhaul tumour cell lines.
Ledford H
Nature; 2016 Feb; 530(7591):391. PubMed ID: 26911756
[No Abstract] [Full Text] [Related]
20. Generation of Multicellular Tumor Spheroids with Microwell-Based Agarose Scaffolds for Drug Testing.
Gong X; Lin C; Cheng J; Su J; Zhao H; Liu T; Wen X; Zhao P
PLoS One; 2015; 10(6):e0130348. PubMed ID: 26090664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
